Telix Pharmaceuticals Ltd: Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade
Telix Pharmaceuticals Ltd: CMS proposes payment improvement for radiopharma diagnostics
Telix Pharmaceuticals Ltd: Notification of cessation of securities - TLX
Telix Pharmaceuticals Ltd: Cleansing Notice
Telix Pharmaceuticals Ltd: Application for quotation of securities - TLX
Telix Pharmaceuticals Ltd: Ceasing to be a substantial holder
Telix Pharmaceuticals Ltd: Ceasing to be a substantial holder from MUFG
Telix Pharmaceuticals Ltd: Pending Release of Shares from Voluntary Escrow
Telix Pharmaceuticals Ltd: Ceasing to be a substantial holder
Telix Pharmaceuticals Ltd: Ceasing to be a substantial holder
Telix Pharmaceuticals Ltd: Ceasing to be a substantial holder from MS
Telix Pharmaceuticals Ltd: Ceasing to be a substantial holder
Telix Pharmaceuticals Ltd: Cleansing Notice
Telix Pharmaceuticals Ltd: Application for quotation of securities - TLX
Telix Pharmaceuticals Ltd: Appendix 3Y Change in Director Interests - C Behrenbruch
Telix Pharmaceuticals Ltd: Notification regarding unquoted securities - TLX
Telix Pharmaceuticals Ltd: Telix Elects to Withdraw from Proposed U.S. Listing
Telix Pharmaceuticals Ltd: Trading Halt
Telix Pharmaceuticals Ltd: Telix Launches Proposed US IPO
Telix Pharmaceuticals Ltd: Telix Completes TLX250-CDx (Zircaix) BLA Submission
No Data